Liver AMPK activation vs ovarian insulin-signaling repair in PCOS
Hyperinsulinemia pushes ovarian theca cells to overproduce androgens.
Insulin resistance forces the pancreas to secrete more insulin.
Excess insulin binds ovarian theca cell receptors directly.
This amplifies LH-driven androgen synthesis abnormally.
High androgens block normal follicle selection each cycle.
Follicles stall, and ovulation becomes rare or absent.
Irregular cycles and infertility commonly follow.
Hyperinsulinemia, not androgens alone, is the primary treatable driver.
Two therapies target insulin signaling from different angles.
Metformin acts mainly in the liver and muscle.
Inositol acts mainly inside the ovarian cell itself.
Metformin lowers blood glucose mainly by quieting the liver.
Metformin inhibits mitochondrial complex I mildly.
This raises AMP relative to ATP inside hepatocytes.
AMPK activates and suppresses gluconeogenic gene expression.
Lower hepatic glucose output reduces circulating insulin demand.
Peripheral tissues become more insulin sensitive over months.
Ovarian androgen production falls as insulin normalizes.
Metformin produces the larger metabolic swing of the two agents.
GI upset is the most common limiting side effect.
Extended-release formulations reduce but do not eliminate it.
Dose titration over weeks improves tolerability meaningfully.
Myo-inositol and D-chiro-inositol repair insulin signal transduction.
Myo-inositol and D-chiro-inositol form IPG mediators.
These mediators carry the insulin signal inside the cell.
PCOS ovaries show a local D-chiro-inositol deficiency.
Supplementation restores the IPG signaling balance directly.
Theca cell androgen overproduction eases as a result.
Granulosa cell insulin response improves alongside it.
Inositol acts locally in the ovary, not primarily the liver.
Inositol is a naturally occurring dietary compound.
Side effects are mild and rare compared to metformin.
This favors long-term adherence in many patients.
Lower hyperinsulinemia lets a dominant follicle finally mature.
Both drugs ultimately lower circulating insulin's ovarian impact.
Lower insulin unblocks normal follicle selection signaling.
A dominant follicle can grow and ovulate again.
Ovulatory response builds gradually over months, not days.
Longer treatment duration compounds the insulin-sensitivity gain.
Early cycles may still be irregular during titration.
Ovulation frequency lags insulin sensitivity by several weeks.
Combining both agents can compound modest synergy.
Combined dosing typically halves each individual contribution.
Clinicians weigh added benefit against added pill burden.
Metformin wins on metabolic power; inositol wins on tolerability.
Metformin produces a larger insulin-sensitivity improvement overall.
Its hepatic mechanism directly targets glucose overproduction.
This makes it preferred for stronger metabolic disease.
Inositol's natural profile causes far fewer side effects.
Higher adherence over time can offset its smaller effect.
Many patients prefer inositol for long-term daily use.
Neither agent is uniformly superior; patient priorities decide.
Combined therapy can suit patients wanting balanced benefit.
Severity of insulin resistance often guides the first choice.
Shared decision-making weighs efficacy against tolerability.